Cysteamine with delayed release (Procysbi®)

The National Health Care Institute Institute carried out an assessment of the medicine cysteamine with delayed release (Procysbi®) whereby they reached the following conclusion.
Based on the criteria of the Medicines Reimbursement System (GVS), cysteamine with delayed release is interchangeable with a product that is included in the GVS.

This report is a summary of recommendations by the National Health Care Institute. The original text is in Dutch.